It is well established that telomerase reverse transcriptase (TERT), Catenin β1 (CTNNB1), and TP53 are the most commonly mutated genes in association with the HCC development, yet the exploration of targeted therapies against these oncogenic driver genes genetic drivers remains unsuccessful [37, 38], highlighting the importance of developing new targeted therapeutics for patients with HCC. Here, CTNNB1 is linked to hepatocellular carcinoma.